Engrail Therapeutics Inc.

Engrail Therapeutics Inc. supports clinical research in focal epilepsy, with an emphasis on patients experiencing partial onset seizures. Its trial activity includes evaluation of adjunctive treatments for seizure control in people already receiving antiseizure therapy.

• Focal (partial onset) seizures
• Adjunctive antiseizure treatment
• Seizure frequency and control

The sponsor’s epilepsy-focused studies are centered on improving management options for individuals with persistent seizures despite standard treatment.